A blood test now in the works could be a better predictor of prostate cancer than current PSA tests. It's called the IsoPSA. It's being developed by the Cleveland Clinic, the Cleveland VA Medical ...

IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland ...

A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today two ...

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company, announced an agreement designed to expand patient access to Cleveland Diagnostics’ novel prostate cancer test, IsoPSA. Through an ...

A PSA or test prostate-specific antigen test after 50 years of age is usually advised to men to check on the status of their prostate gland. An elevated level of PSA in the blood is seen as an ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the ...

CLEVELAND, January 26, 2026--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, has named Michael Iskra as its new Chief Executive Officer. Iskra ...

Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced that the US Food and Drug Administration (FDA) has approved the company’s IsoPSA in vitro diagnostic ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an ...